Introduction
Despite the extensive experience using cryopreserved products in autologous stem cell transplantation, the transplant community has generally favored the use of fresh donor stem cells in patients undergoing allogeneic stem cell transplantation. This is based in large part on theoretical concerns that the cryopreservation and thawing process may damage T cells and other mononuclear cells (MNC) resulting in delayed engraftment and hindrance of a graft-versus-tumor effect. Other concerns arise over the increased risk of transfusion reactions due to the presence of DMSO as a cryoprotectant, a higher risk of bacterial contamination due to increased manipulation steps and a higher risk of subjecting the donor to a potentially unnecessary procedure. As a result, the use of cryopreserved grafts has historically been reserved for extreme circumstances when donor reliability and availability are called into question. While the exact incidence is unknown, preliminary estimates from the Center for International Bone Marrow Transplant Research (CIBMTR) and National Marrow Donor Program (NMDP) suggest that while the use of cryopreserved products for allogeneic transplantation has increased over the last several years, the total has nonetheless constituted o2% of the total number of unrelated transplants facilitated by the NMDP (R King; NMDP, personal communication). This increase is likely based in part on the increased ease of coordinating a transplant with a cryopreserved graft.
In this review, we analyze the available literature that provides insight into the potential pros and cons of using a cryopreserved or fresh stem cell product for allogeneic transplantation. We focus on clinically significant outcomes, such as differences in engraftment, survival, graft-versus-host disease (GvHD), transfusion reactions, bacterial contamination and address logistical differences between the two approaches as well. We suggest that the available literature to date does not sufficiently justify the dogmatic use of fresh over frozen donor grafts. We also propose potential avenues of future investigation to better elucidate this issue. myelogenous leukemia (AML) 1 month apart and underwent staggered allogeneic bone marrow transplants from their older HLA identical brother. The donor was subjected to one harvesting procedure and thus, one twin received fresh donor cells and the other received an equal number of cryopreserved MNC for transplantation 1 month later. In this report, the times to neutrophil (ANC4500 Â 10 9 /l) and platelet (plt450 Â 10 9 /l) engraftment were similar in the two recipients. Each experienced uneventful, grade I-II acute GvHD and were in complete remission at 4 years of follow-up with no evidence of chronic GvHD. 1 When considering fresh versus frozen allogeneic stem cell products, two related issues are of great importance; (1) is there a detectable difference in the cellular content of the grafts which can be attributed to the freeze/thaw process and (2) do these differences in graft content correlate with clinically significant end points such as the incidence of GvHD, relapse rates, time to engraftment and survival? No prospective, randomized trials comparing outcomes for patients receiving cryopreserved donor stem cells to patients receiving fresh donor stem cells for allogeneic stem cell transplant have been performed. In addition, there have been no prospective comparisons of allogeneic graft content before and after cryopreservation with adequate statistical power to draw conclusions. The reported clinical experience as summarized in Table 1 , is limited to small case series and retrospective cohort studies from individual institutions. [1] [2] [3] [4] [5] [6] These studies report on a total of 67 patients who received a cryopreserved stem cell product (57 from related donors, 10 from unrelated donors) and all used bone marrow as a stem cell source. The reported experience on using a cryopreserved product with peripheral blood as a stem cell source is limited to a single case report, 7 although data from the CIBMTR suggest that the practice is becoming increasingly common among transplant centers as noted above. The available literature on the effects of cryopreservation on donor lymphocyte infusion (DLI) is scarce as well. 8 For the most part, these uncontrolled studies compare small numbers of heterogeneous patients (with respect to disease type, disease stage, preparative regimens, GvHD prophylaxis and numbers hematopoietic stem cells infused) and reflect significant investigator bias with respect to reasons for the use of cryopreserved products. While these studies are all underpowered and subjected to the above limitations, they suggest no significant differences in time to engraftment or Day 100 survival. One study suggests a decreased incidence of acute GvHD in recipients of a cryopreserved product. 2 These studies are discussed in more detail below in the context of specific outcomes of interest.
Engraftment
Total number of infused CD34 þ stem cells has been correlated with time to platelet and neutrophil reconstitution. [9] [10] [11] [12] Most of these observations, however, have been reported in autograft (as opposed to allograft) recipients. Of interest, engraftment outcomes in these studies are correlated with pre-frozen CD34 þ numbers. One group recently analyzed numbers of CD34 þ cells, MNC and colony forming units (CFU-GM) in the pre-and post-thaw grafts of 126 patients who underwent autologous peripheral blood (83) or bone marrow (43) transplantation. Pre-and post-thaw CD34 þ cells were well correlated with each other while pre-and post-thaw MNC and CFU-GM were less well correlated. Appropriate analyses to determine if the reductions in post-thaw numbers were statistically significant were not undertaken. Consistent with prior published data, univariate and multivariate analysis found total CD34 þ cells infused to be the only factor predictive of engraftment outcomes. 12 In the allogeneic transplant population, several other cell types of donor origin in addition to CD34 þ progenitors, such as NK cells and CD8 þ T cells have been implicated in engraftment. [13] [14] [15] Effects of cryopreservation/thawing on these cell subsets is even more limited. The scanty literature for times to engraftment in recipients of a cryopreserved allogeneic graft is summarized in Table 1 . While limited, these studies show no difference in significant clinical outcomes such as time to platelet and neutrophil engraftment or day 100 survival when compared with institutional or historic controls. [2] [3] [4] [5] [6] [7] Some of these studies attempted to correlate engraftment outcomes with assessments of fresh and frozen graft contents as summarized in Table 2 . Of note CD34 þ cell numbers were not reported in any of Table 1 Summary of engraftment and outcome data for selected reports of allogeneic stem cell transplantation using cryopreserved stem cells these studies, reflective of the dates of publication and date of widespread availability of this assay. Fresh and frozen graft MNC, CFU-GM and burst-forming units (BFU-E) thus were compared; factors which are less well correlated with engraftment outcomes. Overall, the results were heterogeneous with some studies revealing no differences in fresh and frozen graft contents, [4] [5] [6] and some revealing small, yet statistically significant reductions of CFU and MNC between frozen and fresh grafts.
2,3
The largest reported experience using cryopreserved bone marrow for allogeneic stem cell transplant comes from three reports by Stockschlader et al. [4] [5] [6] In their largest reported series, the authors retrospectively reviewed 40 patients who underwent allogeneic bone marrow transplant from related donors with cryopreserved bone marrow and compared them with a cohort of 40 controls matched for age, disease and disease stage who underwent fresh bone marrow transplant from related donors. 4 Information on donors was not available. Indications for cryopreservation appeared to be independent of disease status and included concerns regarding donor age, reliability, scheduling and operating room availability. The cryoprotectant was dimethylsulphoxide (DMSO) (final concentration 10%) and freezing was accomplished using a controlled-rate programmable freezer. The median time (range) of cryopreservation was 17.5d (3-455d). All patients with two exceptions received the same GvHD prophylaxis with cyclosporine (CSA) and methotrexate (MTX). Conditioning regimens were similar and based on institutional standards for underlying disease. In their analysis no statistically significant differences were found in time to neutrophil and platelet engraftment or day 100 survival 4 (Table 1) . To explore potential correlations between graft content, cryopreservation and engraftment outcomes they analyzed the number of BFU-E, CFU-GM and MNC infused into the recipients (see Table 2 ). No statistically significant difference in the numbers of BFU-E or CFU-GM infused into recipients of a fresh versus a cryopreserved product was found. Prior published results from a subset of 19 of these patients who received a cryopreserved product directly measured the impact of cryopreservation and thawing on graft content by comparing the CFU-GM and MNC numbers before and after cryopreservation. This analysis revealed no statistically significant difference in the prefrozen and post-thaw numbers of CFU-GM and MNC. 5 These findings are consistent with the clinical observation that engraftment times between the two groups were similar.
The same group reported their more limited experience with using cryopreserved bone marrow for 10 patients undergoing unrelated allogeneic transplantation. 6 Engraftment outcomes in these patients were not directly compared to matched or historical controls (Table 1) . Two other small series from the early 1990s each containing less than 10 patients who received transplantation from a cryopreserved product also showed no significant reduction in time to platelet or neutrophil engraftment and day 100 survival when compared to institutional or historic controls. 2, 3 Similar to the studies by Stockschlader et al., these studies also performed analyses of graft content (Table 2) . One study found a small reduction in pre-frozen and postthaw CFUs, but no clinical correlations were reported. 3 
GvHD
An intriguing study by Eckardt et al. 2 reported a statistically significant reduction in the incidence of GvHD for 10 recipients of cryopreserved bone marrow compared Table 2 Summary of comparative graft contents in selected reports of allogeneic stem cell transplantation using fresh versus cryopreserved cells
Reference Storage time cryopreserved grafts Analysis limited to Results
Stockschlader et al. Freezing of allogeneic stem cells NV Frey et al with 33 unmatched institutional controls. Recipients of cryopreserved products had a 20% incidence of grade 1-4 acute GvHD compared to a 56% incidence in the control group (no incidence rates for grade-specific GvHD were reported). Indications for cryopreservation in this study were limited to issues of donor reliability and availability.
No information on donor characteristics were reported. Significant differences between the two recipient groups included age, disease type, disease stage and type of GvHD prophylaxis. Nine of 10 patients who received a cryopreserved product were treated with CSA and MTX for GvHD prophylaxis compared with only 50% of patients in the control group. GvHD prophylaxis for the remaining patients in the study consisted of CSA and corticosteroids, a possible factor in the differences in GvHD reported. Of importance, attempts to account for the differences in characteristics between the two groups using a statistical regression model failed to identify cryopreservation as an independent predictor of GvHD. Other studies described above and summarized in Table 1 have shown no statistically significant reduction in the incidence of acute GvHD. [4] [5] [6] Of note, none of these studies were powered to detect a 10% reduction in GvHD and all subjects in these studies received bone marrow as the source of stem cells. Outcomes between fresh and frozen peripheral blood grafts would be of interest given the higher incidence of GVHD in peripheral blood graft recipients and different mononuclear cell content in peripheral blood grafts. 16 Eckardt et al. suggested that a potential reason for a lower incidence of GvHD in recipients of cryopreserved products could result from the preferential destruction of T cells during the freeze-thaw process, a hypothesis with surprisingly little exploration in the literature. The reported experience regarding the impact of cryopreservation on the viability and functionality of MNC is quite limited. Early studies using crude estimates of T cell number and function suggested no significant reduction in T cell percentage or function after the cryopreservation and thaw process. 17, 18 A more recent investigation incorporating flow cytometry and more sophisticated functional analysis has showed a small but statistically significant reduction in the percentage of CD3 þ , CD4 þ and CD8 þ cells after cryopreservation and 3 months of storage. 19 The assessment of functionality of T cell subsets (and other MNC) after cryopreservation deserves further investigation.
Transfusion reactions
Patients undergoing autologous stem cell transplantation using cryopreserved marrow have a statistically significant increased incidence of transfusion-related nausea, vomiting, fevers and chills when compared to allogeneic recipients of fresh marrow. 20 These symptoms are for the most part transient, well tolerated and are generally not associated with more clinically significant adverse outcomes. These transfusion-related symptoms are, in large part, due to the presence of DMSO which is the most commonly used cryoprotectant and is traditionally present in a 10% final concentration in cryopreserved donor grafts. Stroncek et al. 20 conducted a large retrospective analysis comparing transfusion reactions among 134 recipients of autologous cryopreserved marrow and 71 recipients of fresh allogeneic marrow. A statistically significant increase in the incidence of nausea (45 versus 14%; Po0.0005), vomiting (24 versus 9%; Po0.01) and fever (18 versus 0%; Po0.005) was found in the patients receiving cryopreserved products. No differences were found, however, in serious transfusion reactions marked by hemodynamic instability or pulmonary compromise.
Bacterial contamination
Investigators in this same series reported a 12.7% incidence of bacterial contamination in cryopreserved bone marrow stem cell products that had been thawed. This level of bacterial contamination has been confirmed by other studies. While bacterial contamination can result in febrile reactions and bacteremia in transplanted recipients, it is very unlikely to correlate with more serious adverse outcomes. [20] [21] [22] [23] This increased rate of bacterial contamination appears due to increased manipulation of a cryopreserved product as compared with a fresh product. This finding is supported by a large study in which investigators performed microbial cultures on 194 bone marrow grafts in different stages of processing and showed an increased number of positive bacterial cultures after certain cryopreservation and thawing procedures. 21 Of note there is a lower incidence of bacterial contamination with the use of peripheral blood stem cell products owing to the use of a closed apheresis system to collect cells and the avoidance of multiple punctures through the skin. 23 Also of note, cryopreservation storage bags are structurally improved leading to less breakage and subsequent contamination during thawing procedures.
Logistics
Coordination of the patient's myeloablative conditioning regimen with donor stem cell harvest often is logistically challenging when the use of a fresh product is desired. Donor availability on the day of planned product infusion is influenced by his/her geographic location, vocation and concurrent health status. Securing operating room or apheresis time along with the necessary ancillary staff is sometimes difficult. While a rare event, there is always the possibility that a donor will become unavailable for unforeseen circumstances after the conditioning regimen has been initiated. The use of a cryopreserved product would introduce a greater amount of flexibility into the system and would inherently be more convenient for the donor. The psychological stress on part of the recipient would be lessened as well. Potential feelings of guilt over inconveniencing family members would be minimized by streamlining the donor experience. From an institutional perspective, the enhanced ability to optimize bed utilization and total body irradiation (TBI) slots with pre-planned infusion schedules during 'daytime work hours' would have to be balanced against the increased cost of stem cell cryopreservation and storage. Although, the overall cost-benefit analysis of utilizing fresh versus frozen products is complex and beyond the scope of this article, one should not assume that the costs of cryopreservation will outweigh the potential 'hidden' savings of streamlining bed utilization, TBI scheduling and optimal scheduling of stem cell laboratory personnel.
There is also a 2-5% inherent risk that a donor undergoing peripheral blood stem cell collection will be a 'poor mobilizer', a disconcerting finding if discovered on 'day 0' of transplant. 24, 25 While this issue may become a moot point with the recent reported mobilization success rates of AMD-3100 (a CXCR-4 antagonist), the collection of certain donors at high risk for mobilization-failure ahead of time may be appropriate. 26 The increased use of cryopreserved products raises the possibility of an increase of collected, but not utilized grafts. This raises ethical concerns about subjecting more donors to the time-consuming and potentially harmful harvesting procedure in the event that the transplant is cancelled. If collection of stem cells were undertaken closer in time to the transplant (e.g. within 30 days), the incidence of unnecessary harvesting procedures would be minimized while maintaining many of the benefits mentioned above. The practicality of this approach is supported by the reported experience of Stockschlader et al. 4 (discussed in detail above) who noted a median time for graft cryopreservation and storage of 14.7 days.
DLI
The impact of cryopreservation on graft content and clinical outcomes for DLI is an interesting area, which has not been formally studied. If the observation by Eckardt et al.
2 that cryopreservation may ameliorate GvHD is valid, one would be concerned that the graft-versus-leukemia (GvL) effect being sought by DLI could be amelioriated as well. The feasibility of collecting and freezing a DLI product at the time of original donor collection has been described. One group reported their experience with 17 patients at high risk for relapse whose donors underwent donor lymphocyte collection with cryopreservation at time of original harvest. DLI was given to transplant recipients without GvHD at pre-specified time points with the goal of preventing recurrent disease (i.e., prophylactic DLI). While this study was not designed to assess efficacy of a cryopreserved versus a fresh DLI product, it suggests that cryopreservation of donor lymphocytes at the time of collection for subsequent reinfusion in high risk patients may be a reasonable strategy to avoid delay of DLI in event of relapse. 8 
Future considerations and conclusions
As summarized in Table 3 , we have highlighted many of the potential pros and cons of using fresh versus cryopreserved Table 3 Potential advantages and disadvantages of using cryopreserved stem cell products over fresh stem cell products for allogeneic stem cell transplantation
Potential disadvantages Comments
Concern over delay of neutrophil and platelet engraftment due to damage of the graft during cryopreservation.
The limited published experience shows no significant delay in time to platelet or neutrophil engraftment. Further more appropriately powered studies with laboratory correlates are needed.
Increased incidence of transfusion reactions due to the presence of DMSO as a cryoprotectant.
Cryopreserved products are associated with more transfusion-related nausea, vomiting and fevers but not necessarily more serious events such as hemodynamic instability or pulmonary compromise.
Increased incidence of bacterial contamination of the graft due to increased handling in the freeze/thaw process.
Higher rates of bacterial contamination do not translate into significantly higher rates of bacteremia and sepsis in recipients. Peripheral blood grafts correlate with a lower incidence of contamination.
Increased incidence of collecting grafts which are never utilized, putting the donor through an unnecessary harvesting procedure.
Timing of collection within 1-3 weeks of transplant would minimize this inevitable outcome.
Potential advantages Comments
Decreased stress on the healthcare system. Coordinating donor collection with Day 0 of transplant is challenging. Cryopreservation introduces greater flexibility into the system.
Decreased stress on the donor. Greater flexibility for donor to schedule collection in setting of other obligations.
Identification of donors who are poor mobilizers before Day 0 of transplant Encouraging mobilization results of AMD-3100 may decrease current 2-5% poor mobilization rates among healthy peripheral blood stem cell donors.
Ensured availability of donor graft in event of donor death or unavailability.
While rare, cryopreservation would allay this commonly reported fear among recipients.
Decreased incidence of GVHD owing to preferential destruction of T cell subsets in the cryopreservation process.
Most of the limited clinical and laboratory studies to date do not support this hypothesis. More appropriately powered clinical studies with laboratory correlates are needed.
stem cell grafts for allogeneic stem cell transplantation. While the standard of care currently supports the use of a fresh product, CIBMTR data (D Confer, personal communication) reveals that many individual centers are changing their treatment paradigm to more frequently use frozen products in the allogeneic setting. The studies performed to date comparing clinically significant outcomes, such as time to engraftment, incidence of GvHD and survival are grossly underpowered and subject to the biases inherent in single institutional retrospective reviews. Further studies appropriately powered to assess for these important clinical end points need to be performed. Also, of significance, the reported clinical studies to date are limited to recipients of bone marrow allografts. Unpublished observations by the CIBMTR and the NMDP suggest that up to 80% of transplants are currently being performed with peripheral blood allografts. Given the different composition of these grafts and different observed clinical outcomes such as times to engraftment and incidence of GvHD, further study of this population is warranted. There is also a paucity of data on the impact of cyopreservation on outcomes with DLI. Indeed, if the initial observations of Eckardt et al. for a reduction in GvHD are confirmed, the implication that cryopreservation could have a negative impact on the antitumor immune potential of DLI, as well as the primary graft, is very real. On the other hand, the current debate over the optimal choice of stem cell source, bone marrow versus peripheral blood, and the inherently higher risk of acute and chronic GvHD associated with the later, could be impacted by the observation that cryopreservation has an ameliorating effect on the incidence of GvHD. Is it possible that freezing peripheral blood stem cells, with its higher T-cell content, could bring the products 'closer together' in terms of GvHD incidence without loss of GvL?
At the 2006 American Society of Blood and Bone Marrow Transplant Meeting, we proposed a retrospective cohort study using the CIBMTR database to compare clinical outcomes between recipients of an unrelated cryopreserved graft with recipients of unrelated fresh donor grafts. A preliminary screen of the database identified 263 patients who have received a cryopreserved graft from an unrelated donor since 1999. The study is thus feasible and adequately powered to evaluate differences in important clinical outcomes such as GvHD and time to engraftment while appropriately controlling for known confounders for these outcomes in the analysis. In addition, prospective studies to better describe the effects of the freeze-thaw process on graft content including total CD34 þ cells and T cell number and function are warranted and would be feasible. A prospective study to correlate how these potential differences in graft content and function may correlate with significant clinical outcomes is likely to be more difficult and would require a multi-institutional effort. Results of our retrospective study will provide focus for appropriate subgroups and clinical outcomes to be evaluated in appropriately powered prospective randomized trials.
